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The chosen topic to research is 
Diabetes Mellitus Type II (DMII).  
DMII has become a rampant 
disease in the United States and is 
becoming more common.  The 
United States has an alarming rate 
of new diagnosis of DMII (Chen, 
2012).  One of the most 
disappointing facts is that it can 
be prevented.  DMII is not a 
disease that one has to have for a 
lifetime. An important detail of 
this disease is that it has so many 
comorbidities.  Many people in 
the general population think that 
they can just take a pill or take 
insulin to control it.  However, 
even this will not be enough to 
counteract the debilitating, and 
possibly life ending, symptoms of 
this disease.
There are many signs and symptoms of diabetes.  
While polyuria, polydipsia, and polyphagia may be 
common symptoms, they are not always all present 
with DMII and can sometimes be (Scheen, 2012).  
DMII symptoms often develop slowly and it’s very 
possible to have the disease and not know it.  Other 
symptoms include fatigue, weight loss, blurred 
vision, and slow healing wounds (Scheen, 2012).  
Common signs and symptoms of type 2 diabetes 
include fatigue, especially after eating as well as 
feeling hungry even after you have just eaten.  
Many people also experience polyuria as well as 
polydipsia. Others experience slower wound healing 
times as well as frequent infections and other skin 
issues such as psoriasis. Type 2 diabetics may also 
experience increased hunger.  This is due to the lack 
of insulin moving sugar into cells which will then 
cause muscles and organs to being triggered into 
thinking they are starving (D’Adamio & Capril, 2011).
Signs and Symptoms Underlying and Significance of Pathophysiology
DMII is occurs when the body becomes resistant to insulin or when the pancreas stops producing enough 
insulin.  It is not known why this happens, but factors such as obesity and genetics can play a factor in 
developing this disease (McCance & Huether, 2014). Other factors that may illicit this disease are factors such as 
poor diet, increased stress, smoking, and history of or current medical conditions. 
These factors lead to insufficient amounts of insulin from the beta cells in insulin resistance. Normally, the 
liver will suppress glucose being released into the body.  However, with insulin resistance cells are not able to 
react to normal levels of insulin. This is also associated with increased breakdown of lipids and higher retention 
of salt and water in the kidneys.  It is important to note that not all people with insulin resistance will develop 
DMII (D’Adamio & Capril, 2011). Many people will not develop DMII and have classic symptoms while others are 
genetically inclined to develop the disease.
Insulin resistance is the crux of DMII. Insulin resistance happens when cells fail to normally respond to the 
hormone insulin. Normally the body will release insulin in the presence of glucose in the blood stream and 
utilize glucose instead of fat for energy. When insulin resistance is not present, the body will use glucose 
appropriately and level will remain within normal limits.  When insulin resistance is present it prevents the cells 
from utilizing glucose and leads to hyperglycemia. Hyperglycemia will eventually start to impair beta cells (b 
cells), in the pancreas, and cause more insulin to be produced therefore creating an even higher level of insulin 
in the blood and development of DMII (McCance & Huether, 2014). 
One of the key components in nursing care 
for DMII patients is education.  Education on 
not only the disease and its consequences, 
but education on lifestyle choices that can 
help end DMII. Betterment of nutrition and 
exercise are far more effective than taking 
medications (D’Adamio & Capril, 2011). This 
along with management of the comorbidities 
while they disease is in process will be the 
main talking points for nurses.  While the 
patient is experiencing the disease it is 
important to monitor blood glucose and lab 
levels. Regular follow up with the Primary 
physician or clinic is key to managing and 
defeating DMII.
Conclusion
DMII can be a debilitating and lethal 
disease if not properly managed (McCance & 
Huether, 2014).  The complications of insulin 
resistance and sensitivity become the 
beginning of a slippery slope of a downward 
health spiral.  DMII does not have to be a 
lifelong disease.  Proper diet and exercise can 
decrease the chances of this disease and help 
avoid all its comorbidities. 
Implications of Nursing Care
Obesity is one of the largest contributors to the disruptions in several functions in the body.  Insulin 
resistance leads to elevated levels of free fatty acids which can lead to the changes in insulin incretin and 
glucagon secretion which can lead to inflammation. Inflammation of cytokines from the abdomen can 
contribute to insulin resistance and can also lead to fatty liver, atherclerorsis, and dyslipidemia (De La 
Heras, 2017). 
The most significant change in DMII is that there is an alteration in the balance between insulin sensitivity 
and insulin secretion.  The change in glucose metabolism is from the fall in B-cell function which damages 
the pathways of insulin sensitivity and secretion. Studies suggest that diabetes does not develop until B-
cells fail completely in regard to compensation for the peripheral insulin resistance state, however, the 
progressive nature of DMII indicates a progressive decline in B-cell function (Chen, 2012). This along with 
the other factors including B-cell mass can affect the B cell function loss. This can be due to metabolic 
changes such as insulin resistance, however, other studies suggest that pre-existing conditions as well as 
genetics can play a great factor in determining risk for development of the DMII. Early onset of DMII 
increases risk of mortality and other comorbidities.
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